We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Chang Gung Memorial Hospital.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: May 16, 2012
Last Update Posted: May 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Chang Gung Memorial Hospital
The purpose of this study is to understand the effect of using oral U-relax on HPV infected women for vaginal environment health promotion, and the HPV DNA Test Index change from positive to negative. Long-term infection of HPV is associated with cervical cancer. U-relax contains Lactobacillus GR-1 and Lactobacillus RC-14 and has been approved of its benefits on treatment of BV, UTI, IBD and can improve vaginal environment health. Patients with positive result of HPV DNA test have no appropriate and aggressive treatment to reduce the risk of cervical cancer. This clinical trial tries to reveal the influence of oral U-relax and patients with HPV DNA test positive result.

Condition Intervention Phase
Human Papillomavirus Vaginal Infection Dietary Supplement: U-relax Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Study ,Oral U-relax in the Influence of the Vaginal Environment Health Promotion, and the HPV DNA Test Index Change From Positive to Negative on the HPV Infection Women

Resource links provided by NLM:

Further study details as provided by Chang Gung Memorial Hospital:

Primary Outcome Measures:
  • Vaginal environment health check [ Time Frame: up to Day 360 ]
    PAP Test, general check and health condition questionnaire

Secondary Outcome Measures:
  • HPV DNA Index Test Change [ Time Frame: Day 1, Day 360 ]
    HPV DNA Index Test, Health Condition Check

Estimated Enrollment: 80
Study Start Date: June 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: U-relax
Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
Dietary Supplement: U-relax
Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
Other Name: GR-1 and RC-14

Detailed Description:
This study is a prospective, double blind, randomized clinical trial. Vaginal health screening and HPV DNA Test are carried out from 80 patients with positive HPV DNA Test after conization for 6 months. All these patients will participant this study during the 360-day trial period. All health related conditions will be monitored at the same time.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • female
  • age over 30
  • HPV DNA Index Test with POSITIVE result after conization for 6 months
  • not pregnant

Exclusion Criteria:

  • cervical intraepithelial neoplasia before conization
  • cervical cancer patient
  • with GI surgery
  • GI dysfunction
  • need for long-term antibiotics treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01599416

Contact: Yu-Che Ou, MD +886-7-732-7123 ext 8916 tedycou@gmail.com
Contact: Hao Lin, MD +886-7-732-7123 ext 8916 haolin@adm.cgmh.org.tw

Kaohsiung Chang Gung Memorial Hospital Recruiting
Kaohsiung, Taiwan
Contact: Yu-Che Ou, MD    +886-7-732-7123 ext 8916      
Sponsors and Collaborators
Chang Gung Memorial Hospital
Study Director: Yu-Che Ou, MD CGMH
Principal Investigator: Hao Lin, MD CGMH
  More Information

Responsible Party: Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT01599416     History of Changes
Other Study ID Numbers: CGMH-O&G-201101TF01
99-0948A3 ( Other Identifier: CGMH )
First Submitted: May 7, 2012
First Posted: May 16, 2012
Last Update Posted: May 16, 2012
Last Verified: April 2012

Keywords provided by Chang Gung Memorial Hospital:
Oral Probiotics
HPV DNA Index Test
Vaginal infection

Additional relevant MeSH terms: